Form 8-K PACIFIC BIOSCIENCES OF For: Nov 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Pacific Biosciences of California (PACB) PT Raised to $32 at Cowen
November 3, 2021 6:30 AM EDTCowen analyst Dan Brennan raised the price target on Pacific Biosciences of California (NASDAQ: PACB) to $32.00 (from $30.00) while maintaining a Market Perform rating.
The analyst commented, "PACB reported a good 3Q, with revenues +83% Y/Y, ~5% ahead of expectations, and service, consumables, & instrument revenues... More
